Evidence-practice gaps in P2Y<sub>12</sub> inhibitor use after hospitalisation for acute myocardial infarction: findings from a new population-level data linkage in Australia.

MO, Falster; AL, Schaffer; A, Wilson; A, Nasis; LR, Jorm; M, Hay; K, Leeb; SA, Pearson; D, Brieger

doi:10.1111/imj.15036

Public

Evidence-practice gaps in P2Y12 inhibitor use after hospitalisation for acute myocardial infarction: findings from a new population-level data linkage in Australia.

Shared by NobleBlocks on Feb 1, 2022 • 12:00 AM UTC

Authors:

Falster MO

Schaffer AL

Wilson A

Abstract

Background P2Y12 inhibitor therapy is recommended for 12 months in patients hospitalised for acute myocardial infarction (AMI) unless the bleeding risk is high.Aims To describe real-world use of P2Y12 inhibitor therapy following AMI hospitalisation.Methods We used population-level linked hospital da...

Subject

Acute myocardial infarction

Medication Adherence

Dual Antiplatelet Therapy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!